Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Licenses SiRNA Selection Algorithm from Novartis

NEW YORK, Dec. 15 (GenomeWeb News) - Qiagen said today that it has licensed from Novartis a novel algorithm for the selection of siRNAs for RNA interference applications.


Under the terms of the deal, Qiagen made an undisclosed payment to Novartis for the worldwide use of the algorithm. Additional terms were not given.


Since acquiring Xeragon in 2002, Qiagen has introduced a number of RNAi products, including custom siRNA duplexes. Qiagen also signed a deal in August to provide Novartis with a genome-wide library of siRNAs for dr4ug discovery.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.